9 Results for "

Atypical kinases

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "Atypical kinases" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-123979
CAS No.: 3316-02-7
Purity:  95.05%
Synonyms: NSC37044
Target:  

PKC Apoptosis

Research Areas:  

Cancer

ζ-Stat (NSC37044) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-123979A
CAS No.: 31894-34-5
Purity:  ≥97.0%
Synonyms: NSC37044 trisodium
Target:  

PKC Apoptosis

Research Areas:  

Cancer

ζ-Stat trisodium (NSC37044 trisodium) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat trisodium can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117596
CAS No.: 1350547-65-7
Purity:  99.92%
Target:  

TAM Receptor

Research Areas:  

Cancer

UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC50 of 2.9 nM and a Ki of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC50s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research
loading...
    loading...
Cat. No.: HY-18713
CAS No.: 1438881-19-6
Target:  

PKC ROCK

CRT0066854 is a potent and selective atypical PKC isoenzymes inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively .
loading...
    loading...
Cat. No.: HY-18713A
CAS No.: 2250019-91-9
Target:  

PKC ROCK

Research Areas:  

Neurological Disease

CRT0066854 hydrochloride is a potent and selective atypical PKCs inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively .
loading...
    loading...
Cat. No.: HY-156792
CAS No.: 1088216-72-1
Target:  

RIO Kinase

Research Areas:  

Cancer

RIOK2-IN-1 (com 4) is a potent and selective RIOK2 inhibitor (Kd=150 nM), but has low cellular activity (IC50=14,600 nM). RIOK2 is an atypical kinase associated with a variety of human cancers and is involved in ribosome maturation and cell cycle progression. The small molecule inhibitor CQ211 (HY-147655), an improvement of RIOK2-IN-1 as the lead compound, has good in vivo and in vitro activity, inhibits the proliferation of MKN-1 and HT-29 cancer cells, and can xenograft MKN in mice -1 model inhibits tumor progression .
loading...
    loading...
Cat. No.: HY-131220
CAS No.: 15854-12-3
Target:  

PKC

Research Areas:  

Inflammation/Immunology

aPKC-IN-1 (compound 1) is an atypical protein kinase C (aPKCζ) inhibitor. aPKC-IN-1 can be used for the study of a host of diseases involving increased vascular permeability and inflammation .
loading...
    loading...
Cat. No.: HY-E70855
Target:  

PKC

Research Areas:  

Cancer

PKCζ is a member of the atypical PKC subfamily and has been widely implicated in the regulation of cellular functions. The major activation pathway of PKCζ depends on phosphatidylinositol (PI)-3,4,5-trisphosphate (PIP(3)), which is mainly produced by PI-3 kinase. PKCζ Recombinant Human Active Protein Kinase is a recombinant PKCζ protein that can be used to study PKCζ-related functions .
loading...
    loading...
Cat. No.: HY-138032
CAS No.: 326914-17-4
Synonyms: N,N-Dimethyl sunitinib
SU11657 (N,N-Dimethyl sunitinib) is an orally active multi-targeted tyrosine kinase inhibitor with IC50 values of 0.04 μM (c-Kit), 0.005 μM (PDGFR), 0.013 μM (VEGFR1), 0.017 μM (VEGFR2) and 50 nM (FLT3), respectively. SU11657 exhibits anti-angiogenic activity. SU11657 delays leukemia progression, synergizes with ATRA (HY-14649) to reduce leukemia burden, and inhibits symptoms and tissue damage associated with rheumatoid arthritis. SU11657 can be used in research related to FLT3-mutated acute promyelocytic leukemia, rheumatoid arthritis, neuroblastoma, and benign/atypical meningioma .
loading...
    loading...